Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

作者：Chong Kin Liam, Azura Rozila Ahmad, Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu · 年份：2025 · DOI：10.1158/1078-0432.30706782 · 研究领域：Lung Cancer Treatments and Mutations、Radiomics and Machine Learning in Medical Imaging、Fibroblast Growth Factor Research

<p>Duration of PFS in the patient subgroup with MET amplification</p>